Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 2/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | STK4 | Q13043 | 1/20 | 0.46 |
| ▸ | STK3 | Q13188 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 5/20 | 0.41 |
| ▸ | STK17B | O94768 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113937 | 0.88 | DHFR (0.55) | DHFRADORA1ADORA2ASYKIRAK4 | |
| SCHEMBL2115771 | 0.86 | DHFR (0.53) | DHFRADORA1ADORA2AHRH4STK4 | |
| SCHEMBL2112549 | 0.86 | DHFR (0.53) | DHFRADORA1ADORA2ASYKIRAK4 | |
| SCHEMBL2116809 | 0.84 | DHFR (0.51) | DHFRADORA1ADORA2ASTK4STK3 | |
| SCHEMBL4118866 | 0.83 | DHFR (0.50) | DHFRADORA1ADORA2AIRAK4HRH3 | |
| SCHEMBL4107262 | 0.83 | DHFR (0.50) | DHFRADORA1ADORA2ASYKIRAK4 | |
| SCHEMBL2115299 | 0.83 | DHFR (0.55) | DHFRADORA1ADORA2AHRH4STK4 | |
| SCHEMBL4101836 | 0.82 | FGFR1 (0.52) | DHFRADORA1ADORA2AIRAK4HRH4 | |
| SCHEMBL4100252 | 0.82 | IRAK4 (0.49) | DHFRADORA1ADORA2AIRAK4HRH3 | |
| SCHEMBL4110576 | 0.82 | DHFR (0.48) | DHFRADORA1ADORA2AIRAK4STK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293525-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | DHFR 1219/4885ADORA1 236/4885ADORA2A 274/4885 |
| US-20090181995-A1 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES | PRKCA, PRKCH, PRKCG | DHFR 1219/4885ADORA1 236/4885ADORA2A 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.